Literature DB >> 9286181

Economic reforms and the acute inpatient care of patients with schizophrenia: the Chinese experience.

M R Phillips1, S H Lu, R W Wang.   

Abstract

OBJECTIVE: This study compared insured and uninsured schizophrenic inpatients in China and examined changes in the acute inpatient care of schizophrenic patients during China's economic reform era.
METHOD: Detailed chart reviews of 50 randomly selected inpatients discharged from a hospital in central China each year from 1984 through 1993 identified 321 patients with schizophrenia. Demographic, insurance, treatment, and cost data of these patients were collected from the charts.
RESULTS: With logistic regression models to control for confounding variables, the analyses showed that the 129 insured patients were significantly more likely than the 192 uninsured patients to be urban residents, to be older, to have had 7 or more years of schooling, and to have had more psychiatric hospitalizations; moreover, their index admissions were longer and were more likely to include use of traditional Chinese medications. The estimated 19% of schizophrenic individuals in the community with health insurance receive inpatient treatment 2.8 times more frequently than the 81% without insurance. Compared to admissions in 1984-1988, admissions in 1989-1993 were significantly shorter and involved longer periods of polypharmacy with multiple antipsychotic medications but included lower mean chlorpromazine-equivalent doses of medication. The relative cost of inpatient care for an acute episode of schizophrenia increased 3.5-fold over the 10-year period, from 11% of mean annual household income in 1984 to 37% in 1993.
CONCLUSIONS: Changes in the incentive system for care providers and rapid increases in the cost of care during the economic reform era have resulted in increasingly restricted availability of services for the many schizophrenic patients without health insurance.

Entities:  

Mesh:

Year:  1997        PMID: 9286181     DOI: 10.1176/ajp.154.9.1228

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  8 in total

1.  Suicide and social change in China.

Authors:  M R Phillips; H Liu; Y Zhang
Journal:  Cult Med Psychiatry       Date:  1999-03

Review 2.  Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Authors:  Juan A Gallego; John Bonetti; Jianping Zhang; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2012-04-24       Impact factor: 4.939

3.  Attitudes toward taking medication among outpatients with schizophrenia: cross-national comparison between Tokyo and Beijing.

Authors:  Naoaki Kuroda; Shiyou Sun; Chih-Kuang Lin; Nobuaki Morita; Hirotaka Kashiwase; Fude Yang; Yoji Nakatani
Journal:  Environ Health Prev Med       Date:  2008-08-12       Impact factor: 3.674

4.  Subjective quality of life in outpatients with schizophrenia in Hong Kong and Beijing: relationship to socio-demographic and clinical factors.

Authors:  Yu-Tao Xiang; Yong-Zhen Weng; Chi-Ming Leung; Wai-Kwong Tang; Gabor S Ungvari
Journal:  Qual Life Res       Date:  2007-11-23       Impact factor: 4.147

5.  Characteristics, experience, and treatment of schizophrenia in China.

Authors:  M R Phillips
Journal:  Dialogues Clin Neurosci       Date:  2001-06       Impact factor: 5.986

6.  Socioeconomic inequality in rehabilitation service utilization for schizophrenia in China: Findings from a 7-year nationwide longitudinal study.

Authors:  Ruoxi Ding; Ping He; Xiaoying Zheng
Journal:  Front Psychiatry       Date:  2022-08-26       Impact factor: 5.435

7.  The personal, societal, and economic burden of schizophrenia in the People's Republic of China: implications for antipsychotic therapy.

Authors:  William Montgomery; Li Liu; Michael D Stensland; Hai Bo Xue; Tamas Treuer; Haya Ascher-Svanum
Journal:  Clinicoecon Outcomes Res       Date:  2013-08-14

8.  Does participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine?

Authors:  William Montgomery; Tamas Treuer; Wenyu Ye; Hai Bo Xue; Sheng Hu Wu; Li Liu; Zbigniew Kadziola; Michael D Stensland; Haya Ascher-Svanum
Journal:  Neuropsychiatr Dis Treat       Date:  2014-07-10       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.